%0 Journal Article %1 Lafon-Hughes2008 %A Lafon-Hughes, Laura %A Tomaso, María Vittoria Di %A Méndez-Acuña, Leticia %A Martínez-López, Wilner %D 2008 %J Mutat Res %K Acetylation Adenosine_Triphosphate,_pharmacology Animals Chromatin_Assembly_and_Disassembly,_drug_effects/physiology DNA_Methylation Epigenesis,_Genetic,_physiology Histone_Acetyltransferases,_metabolism Histones,_metabolism Humans Models,_Biological Neoplasms,_genetics Poly(ADP-ribose)_Polymerases,_metabolism Protein_Processing,_Post-Translational Tumor_Markers,_Biological,_genetics %N 3 %P 191-214 %R 10.1016/j.mrrev.2008.01.008 %T Chromatin-remodelling mechanisms in cancer. %U http://dx.doi.org/10.1016/j.mrrev.2008.01.008 %V 658 %X Chromatin-remodelling mechanisms include DNA methylation, histone-tail acetylation, poly-ADP-ribosylation, and ATP-dependent chromatin-remodelling processes. Some epigenetic modifications among others have been observed in cancer cells, namely (1) local DNA hypermethylation and global hypomethylation, (2) alteration in histone acetylation/deacetylation balance, (3) increased or decreased poly-ADP-ribosylation, and (4) failures in ATP-dependent chromatin-remodelling mechanisms. Moreover, these alterations can influence the response to classical anti-tumour treatments. Drugs targeting epigenetic alterations are under development. Currently, DNA methylation and histone deacetylase inhibitors are in use in cancer therapy, and poly-ADP-ribosylation inhibitors are undergoing clinical trials. Epigenetic therapy is gaining in importance in pharmacology as a new tool to improve anti-cancer therapies.

@article{Lafon-Hughes2008, abstract = {Chromatin-remodelling mechanisms include DNA methylation, histone-tail acetylation, poly-ADP-ribosylation, and ATP-dependent chromatin-remodelling processes. Some epigenetic modifications among others have been observed in cancer cells, namely (1) local DNA hypermethylation and global hypomethylation, (2) alteration in histone acetylation/deacetylation balance, (3) increased or decreased poly-ADP-ribosylation, and (4) failures in ATP-dependent chromatin-remodelling mechanisms. Moreover, these alterations can influence the response to classical anti-tumour treatments. Drugs targeting epigenetic alterations are under development. Currently, DNA methylation and histone deacetylase inhibitors are in use in cancer therapy, and poly-ADP-ribosylation inhibitors are undergoing clinical trials. Epigenetic therapy is gaining in importance in pharmacology as a new tool to improve anti-cancer therapies.}, added-at = {2010-01-26T20:35:53.000+0100}, author = {Lafon-Hughes, Laura and Tomaso, Mar{\'{i}}a Vittoria Di and M{\'{e}}ndez-Acu{\~{n}}a, Leticia and Mart{\'{i}}nez-L{\'{o}}pez, Wilner}, biburl = {https://www.bibsonomy.org/bibtex/2f6c168a7cc21e0ddb8feffc003d082e8/denilw}, doi = {10.1016/j.mrrev.2008.01.008}, institution = {Genetic Toxicology Department, Instituto de Investigaciones Biol{\'{o}}gicas Clemente Estable, Montevideo, Uruguay.}, interhash = {1924f6fe8d03035ffaf8b186f8965827}, intrahash = {f6c168a7cc21e0ddb8feffc003d082e8}, journal = {Mutat Res}, keywords = {Acetylation Adenosine_Triphosphate,_pharmacology Animals Chromatin_Assembly_and_Disassembly,_drug_effects/physiology DNA_Methylation Epigenesis,_Genetic,_physiology Histone_Acetyltransferases,_metabolism Histones,_metabolism Humans Models,_Biological Neoplasms,_genetics Poly(ADP-ribose)_Polymerases,_metabolism Protein_Processing,_Post-Translational Tumor_Markers,_Biological,_genetics}, number = 3, owner = {denilw}, pages = {191-214}, pii = {S1383-5742(08)00030-6}, pmid = {18403253}, timestamp = {2010-01-26T20:36:00.000+0100}, title = {Chromatin-remodelling mechanisms in cancer.}, url = {http://dx.doi.org/10.1016/j.mrrev.2008.01.008}, volume = 658, year = 2008 }